Warburg Pincus will acquire a “significant” minority stake in Sebia, according to a news release.
Sebia, founded in 1967 and with its U.S. headquarters in Norcross, Georgia, is a global provider of specialty diagnostics. The company specializes in vitro diagnostics, providing instruments and reagents for screening and monitoring diseases in oncology, diabetes, hemoglobinopathies, autoimmune and infectious diseases, and other rare disorders.
Warburg Pincus, founded in 1966 and based in New York, is a global private equity firm focused on growth investing. The firm takes a long-term perspective and invests in businesses at all stages of development within healthcare and several other sectors.
Terms of the transaction were not disclosed. Closing is expected to occur no earlier than Q1 2026.